Indole-3-propionic acid (IPA) has emerged as a major player in aging research, showing an ability to extend lifespan in Drosophila and reverse musculoskeletal decline in aged mice. But there’s a snag in the human data. While IPA levels usually track with dietary polyphenol intake, that relationship falls apart in people with impaired renal function (eGFR < 60). I’d argue we’re looking at IPA in a vacuum. To bridge the gap between these animal models and human epidemiology, we have to treat IPA as a competitive antagonist against its toxic sibling—Indoxyl Sulfate (IS).
I suspect the IPA:IS ratio is a much better predictor of biological age acceleration and mortality than absolute IPA levels alone. Mechanistically, IPA likely acts as a homeostatic stabilizer that blocks the pro-senescent signaling of IS. While IS is a known uremic toxin that drives vascular senescence and inflammation through the Aryl Hydrocarbon Receptor (AhR), IPA targets the Pregnane X Receptor (PXR) to strengthen the intestinal barrier and reduce amyloid-β accumulation.
As renal function drops, the body either prioritizes IS clearance or IPA’s protective signaling simply gets drowned out. In this indolic tug-of-war, a high IPA:IS ratio maintains cellular proteostasis and keeps the Senescence-Associated Secretory Phenotype (SASP) in check. Conversely, the low ratio typical of aging and chronic kidney disease speeds up epigenetic aging via AhR-mediated oxidative stress.
The fldC gene cluster in Clostridium sporogenes produces IPA via phenylacetyl-CoA dehydratase. In a healthy gut-kidney axis, IPA





























